跳至主要内容
临床试验/CTRI/2022/01/039317
CTRI/2022/01/039317已完成4 期

Efficacy, Safety, and population pharmacokinetics of low-dose vs. standard dose hydroxyurea in paediatric patients suffering from Sickle cell disease: A randomized double-blind active-control non-inferiority clinical trial.

All India Institute of Medical Sciences0 个研究点目标入组 90 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a)Sickle cell Anemia patients between 6-18 years of age having weight between 15-60 years either on Hydroxyurea or are started on hydroxyurea and characterized by pain episodes in the past. Painful crisis is defined as a presence of pain for 4 or more hours requiring the intervention with any injectable analgesics.
  • b)Patients willing to provide informed consent and assent.

排除标准

  • a)Patients with other forms of sickle cell syndromes.
  • b)Patients on any immunosuppression drugs.
  • c)Patients with abnormal liver function tests.
  • d)Patients allergic to any drug provided during the study period.

研究者

相似试验